Credit: Seth Dixon / St. Jude Children's Research Hospital
First author Amit Budhraja, Ph.D., and senior author Joseph Opferman, Ph.D., determined that the anti-malaria drug (DHA) worked by repressing production of a protein (MCL-1) that promotes survival of a wide variety of cells, including cancer cells.